Estimates Revisions Cadrenal Therapeutics, Inc.

Stocks

Market Closed - Nasdaq 16:00:00 2026-09-09 EDT			5-day change	1st Jan Change
1.190 ^USD	-0.83%		-10.53%	-82.45%

08-31	Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of Cad-1005 in Heparin-Induced Thrombocytopenia	CI
08-13	Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.
CADRENAL THERAPEUTICS, INC.	-	-
WUXI APPTEC CO., LTD.
ARGENX SE
INSMED INCORPORATED
WUXI BIOLOGICS (CAYMAN) INC.
BIONTECH SE
GENMAB A/S
PHARMAESSENTIA CORPORATION
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
EXELIXIS, INC.
Average
Weighted average by Cap.